1110 completed. 1110 Phase 3, 85 Phase 2.
By phase and status
Follow Hypersensitivity: new trials by email Literature Review of Hypersensitivity trials Research Report on Hypersensitivity
Trials (filtered) newest first · largest first
All 1,110 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Research Study of House Dust Mite (HDM) SLIT-tablet for the Treatment of HDM Allergy in Chinese Participants Aged 12-65
HDM SLIT-tablet (12 SQ-HDM), Placebo - Allergic Rhinoconjunctivitis, Allergic Rhinitis | Phase 3 | Completed | 327 | 2025-09-01 | 2026-10-05 |
Oothpaste Containing 8% Arginine Compared to Colgate Cavity Protection Toothpaste in Reducing Dentinal Hypersensitivity
Toothpaste containing 8% Arginine, Colgate Cavity Protection Toothpaste - Hypersensitivity | Phase 3 | Completed | 80 | 2025-07-14 | 2025-12-05 |
Dentinal Hypersensitivity Reduction Efficacy Study
CSPR Toothpaste, Colgate Dental Cream Toothpaste - Sensitivity, Tooth | Phase 3 | Completed | 95 | 2025-03-04 | 2026-03-19 |
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
Fp/ABS, FP, ABS - Asthma | Phase 3 | Completed | 649 | 2024-12-12 | 2026-11-04 |
Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis
Roflumilast Cream 0.15%, Vehicle cream - Atopic Dermatitis (AD) | Phase 3 | Completed | 354 | 2024-11-21 | 2025-09-02 |
A Study to Demonstrate the Effect of REGN5713-5715 on Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Birch Pollen Allergy
REGN5713, REGN5715, Placebo - Allergic Conjunctivitis | Phase 3 | Completed | 54 | 2024-11-19 | 2026-04-21 |
Confirmatory Study on the Efficacy and Safety of the Fixed-dose Combination of Desloratadine/Betamethasone Versus Desloratadine
Desloratadine / Betamethasone in fixed dose, Desloratadine - Allergic Rhinitis | Phase 3 | Completed | 70 | 2024-11-11 | 2026-07-23 |
A Study to Demonstrate How Well REGN1908-1909 Works in Reducing Ocular Allergy Signs and Symptoms in Adult Participants With Cat Allergy
REGN1908, REGN1909, Placebo - Allergic Conjunctivitis | Phase 3 | Completed | 64 | 2024-11-06 | 2026-05-08 |
Clinical of Hypersensitivity Reduction Efficacy on Two Toothpastes
Test toothpaste, Control toothpaste - Hypersensitivity | Phase 3 | Completed | 87 | 2024-10-08 | 2025-04-22 |
Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis
611, Placebo, Topical corticosteroid - Dermatitis, Atopic, Eczema, Atopic | Phase 3 | Completed | 417 | 2024-09-23 | 2026-09-17 |
A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)
PURETHAL Mites 50,000 AUeq/ml, Biological/Vaccine: Placebo - House Dust Mite Allergy, House Dust Mite Rhinitis | Phase 3 | Completed | 691 | 2024-09-09 | 2026-08-10 |
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II
KVD900 150 mg, KVD900 300 mg, KVD900 600 mg - Hereditary Angioedema | Phase 3 | Completed | 36 | 2024-08-01 | 2026-08-05 |
A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma
BDA MDI HFO 160/180 μg, BDA MDI HFA 160/180 μg, Placebo MDI HFA - Asthma | Phase 3 | Completed | 424 | 2024-07-22 | 2026-09-08 |
Fixed Dose Combination of Desloratadine / Prednisolone in the Treatment of Moderate Severe Allergic Rhinitis in Children
Desloratadine , Prednisolone, Desloratadine - Allergic Rhinitis | Phase 3 | Completed | 262 | 2024-07-08 | 2026-10-26 |
A Study to Evaluate the Efficacy and Safety of SIM0718 in Adult and Adolescent Patients With Moderate to Severe Atopic Dermatitis
SIM0718 Injection - Atopic Dermatitis | Phase 3 | Completed | 259 | 2024-07-04 | 2026-03-31 |
To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria
CMAB007, Xolair - Chronic Spontaneous Urticaria | Phase 3 | Completed | 392 | 2024-06-18 | 2026-10-02 |
Lebrikizumab Pen Ease of Use in Participants With Atopic Dermatitis
Lebrikizumab Pen - Atopic Dermatitis | Phase 3 | Completed | 55 | 2024-06-04 | 2025-07-29 |
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma
Salbutamol HFA-134a, Salbutamol HFA-152a - Asthma | Phase 3 | Completed | 471 | 2024-05-31 | 2026-10-06 |
A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis
Ruxolitinib Cream, Vehicle Cream - Atopic Dermatitis | Phase 3 | Completed | 241 | 2024-04-26 | 2026-10-15 |
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
Placebo, Lebrikizumab, Topical Corticosteroid - Atopic Dermatitis | Phase 3 | Completed | 301 | 2024-04-24 | 2026-10-16 |
Showing 20 of 1110. Sign in to see all of them.
Narrower conditions
Asthma (474) · Dermatitis, Atopic (155) · Rhinitis, Allergic, Seasonal (112) · Rhinitis, Allergic (84) · Rhinitis, Allergic, Perennial (73) · Conjunctivitis, Allergic (56) · Eczema (51) · Angioedemas, Hereditary (43) · Chronic Urticaria (28) · Rhinitis (23) · Lung Diseases (21) · Eosinophilic Esophagitis (20) · Dermatitis (17) · Respiratory Tract Diseases (16)
Broader conditions
Immune System Diseases (1099) · Hypersensitivity, Immediate (1034) · Respiratory Tract Diseases (705) · Respiratory Hypersensitivity (704) · Bronchial Diseases (472) · Lung Diseases (468) · Lung Diseases, Obstructive (462) · Skin and Connective Tissue Diseases (261) · Skin Diseases (246) · Otorhinolaryngologic Diseases (236) · Nose Diseases (234) · Rhinitis (211) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (208) · Genetic Diseases, Inborn (201)
Interventions
Budesonide (68) · Fluticasone (67) · montelukast (46) · Budesonide, Formoterol Fumarate Drug Combination (44) · Mometasone Furoate (41) · Albuterol (40) · Formoterol Fumarate (39) · ciclesonide (38) · Beclomethasone (35) · Omalizumab (34) · dupilumab (30) · Salmeterol Xinafoate (25) · fluticasone furoate (21) · desloratadine (20) · Fluticasone-Salmeterol Drug Combination (19)
Sponsors
AstraZeneca (120) · Organon and Co (81) · GlaxoSmithKline (77) · Novartis Pharmaceuticals (36) · Sanofi (28) · Teva Branded Pharmaceutical Products R&D, Inc. (28) · ALK-Abelló A/S (27) · Shire (23) · Chiesi Farmaceutici S.p.A. (20) · Boehringer Ingelheim (19) · Eli Lilly and Company (19) · Sumitomo Pharma America, Inc. (19) · Milton S. Hershey Medical Center (16) · Regeneron Pharmaceuticals (16) · Meda Pharmaceuticals (14)
Countries
United States (507) · Germany (241) · Canada (208) · Poland (176) · Spain (146) · France (139) · Japan (138) · United Kingdom (134) · Italy (129) · Hungary (117) · Russia (103) · Australia (98) · Argentina (90) · Czechia (87) · Netherlands (86)
Top investigators
Catherine Bonuccelli (11)
Results publications
PMID 36472162, PMID 36326435, PMID 39588375, PMID 27881132, PMID 31319851, PMID 35636689, PMID 42162528, PMID 33826132, PMID 34389504, PMID 40993471, PMID 32926419, PMID 34406619, PMID 36255569, PMID 36723913, PMID 38896380, PMID 40028832, PMID 20818886, PMID 23312695, PMID 29174062, PMID 30954640, PMID 31066001, PMID 32180164, PMID 33165005, PMID 33453450, PMID 34037993, PMID 34142350, PMID 36808602, PMID 39104653, PMID 40555305, PMID 41118053, PMID 22329608, PMID 23548529, PMID 23878046, PMID 24712435, PMID 24966061, PMID 25685162, PMID 26054553, PMID 26369589, PMID 26498386, PMID 26612545, PMID 26704701, PMID 27424128, PMID 27540466, PMID 27939380, PMID 28390587, PMID 29655772, PMID 29656145, PMID 30802500, PMID 31047111, PMID 31251094
NIH funding
2015 (18), 2017 (17), 2018 (17), 2016 (16), 2019 (12), 2014 (11), 2023 (11), 2009 (10), U10HL098115 (7), 2004 (6), 2008 (5), U10HL074073 (4), U10HL074204 (4), U10HL074208 (4), U10HL074212 (4)